PerkinElmer Acquires Covaris
December 8, 2023
PerkinElmer has acquired Covaris, a Woburn, Massachusetts-based developer of instruments, consumables, and reagents for high-throughput genomic and proteomic sample preparation. Both companies are majority owned by New Mountain Capital; the acquisition expands PerkinElmer's life-sciences portfolio and accelerates its entry into the diagnostics and NGS sample-preparation market. Terms were not disclosed.
- Buyers
- PerkinElmer
- Targets
- Covaris
- Platforms
- PerkinElmer
- Industry
- Medical Devices
- Location
- Massachusetts, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
New Mountain Capital to Acquire PerkinElmer's Applied, Food and Enterprise Services Businesses
August 1, 2022
Medical Devices
New Mountain Capital entered into a definitive agreement to acquire PerkinElmer's Applied, Food and Enterprise Services businesses (a carve-out from PerkinElmer's Discovery & Analytical Solutions segment) for up to $2.45 billion. The transaction transfers the OneSource lab and field services business and a portfolio of instruments, consumables and reagents to New Mountain, which intends to invest behind the business as a platform for growth; the deal closed in Q1 2023 subject to customary approvals.
-
New Mountain Capital Makes Majority Investment in Covaris
January 13, 2022
Medical Devices
New Mountain Capital has made a majority investment in Covaris, a Woburn, Massachusetts-based manufacturer of sample preparation instruments, consumables and reagents for genomics and proteomics. Founder Jim Laugharn will remain CEO and Chris O'Connell will serve as Executive Chairman as New Mountain partners with Covaris to accelerate growth and expand the company's sample-prep capabilities.
-
PerkinElmer Acquires BioLegend for Approximately $5.25 Billion
July 26, 2021
Biotechnology
PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.
-
PerkinElmer to Acquire SIRION Biotech
June 22, 2021
Healthcare Services
PerkinElmer, Inc. entered into an agreement to acquire SIRION Biotech GmbH, a global provider of viral vector-based technologies for cell and gene therapies. The deal is expected to close in the third quarter of 2021 and will complement PerkinElmer’s Horizon Discovery portfolio and broader cell and gene research solutions.
-
PerkinElmer Acquires Nexcelom Bioscience for $260M
May 13, 2021
Medical Devices
PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.
-
PerkinElmer Acquires Cisbio Bioassays from Abénex
April 26, 2019
Biotechnology
PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.